<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984295</url>
  </required_header>
  <id_info>
    <org_study_id>V221-013</org_study_id>
    <secondary_id>2009_666</secondary_id>
    <nct_id>NCT00984295</nct_id>
  </id_info>
  <brief_title>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</brief_title>
  <official_title>An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Frozen MMRV Given Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines in Healthy Children 12 to 15 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and immunogenicity of ProQuad when administered
      concomitantly and nonconcomitantly with Tripedia and Comvax.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">December 2001</completion_date>
  <primary_completion_date type="Actual">October 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥120 mIU/mL</measure>
    <time_frame>6 Weeks Postvaccination</time_frame>
    <description>Antibody Response to Measles at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer &lt;120 mIU/mL) to Measles at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥10 Ab Units/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody Response to Mumps at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer &lt;10 Ab units/mL) to Mumps at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥10 IU/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody Response to Rubella at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer &lt;10 IU/mL) to Rubella at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Varicella-Zoster Virus (VZV) Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Antibody Titer ≥5 gpELISA Units/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody Response to Varicella-Zoster Virus (VZV) at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer &lt;0.6 gpELISA units/mL) to VZV at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Diphtheria Vero Cell Culture Assay Antibody Titer ≥0.1 IU/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody response to Diphtheria at 6 weeks postvaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Tetanus Enzyme Immunoassay (EIA) Antibody Titer ≥0.1 IU/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody response to Tetanus (tetanus antitoxin were measured with an indirect, noncompetitive enzyme immunoassay (EIA)) at 6 weeks postvaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With ≥4-fold Rise in Pertussis Toxin (PT) EIA Antibody Titer</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody response to Pertussis Toxin (titers of pertussis toxin antibodies were measured with an indirect, noncompetitive EIA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With ≥4-fold Rise in Pertussis Filamentous Hemagglutinin (FHA) EIA Antibody Titer</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody response to pertussis FHA(titers of pertussis filamentous hemagglutinin antibodies were measured with an indirect, noncompetitive EIA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Hepatitis B (Quantitative AUSAB™ Radioimmunoassay (RIA)) Antibody Titer ≥10 mIU/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody response to Hepatitis B (titers measured using the Quantitative AUSAB™ radioimmunoassay (RIA)).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Haemophilus Influenzae Type B (Hib) Radioimmunoassay (RIA) Antibody Titer ≥ 1 mcg/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody response to Haemophilus influenzae type B (Hib). (Anti-polyribosylribitol phosphate (PRP) was measured by radioimmunoassay (RIA) using radiolabeled-PRP according to a standard Farr technique and with a standard provided by the U.S. FDA.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Measles at 6 Weeks Postvaccination for Participants Initially Seronegative to Measles at Baseline - Geometric Mean Titer (GMT)</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination Observed Geometric Mean Titer of Antibody to Measles. (Titers measured using Measles ELISA.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Mumps at 6 Weeks Postvaccination for Participants Initially Seronegative to Mumps at Baseline - GMT</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination observed GMT of antibody to mumps. (Titers measured using mumps ELISA.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Rubella at 6 Weeks Postvaccination for Participants Initially Seronegative to Rubella at Baseline - GMT</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination Observed Geometric Mean Titer of Antibody to Rubella. (Titers measured using Rubella ELISA.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Varicella at 6 Weeks Postvaccination for Participants Initially Seronegative to Varicella at Baseline - GMT</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination Observed Geometric Mean Titer of Antibody to Varicella. (Titers measured using VZV gpELISA.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Diphtheria at 6 Weeks Postvaccination - GMT</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination Observed Geometric Mean Titer of Antibody to Diphtheria. (Titers measured using Vero Cell Culture Assay.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Pertussis Toxin (PT) at 6 Weeks Postvaccination - GMT</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination Observed Geometric Mean Titer of Antibody to Pertussis Toxin (PT). Titers measured using an indirect, noncompetitive Pertussis enzyme immunoassay (EIA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Pertussis Filamentous Hemagglutinin (FHA) at 6 Weeks Postvaccination - GMT</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination Observed Geometric Mean Titer of Antibody to Pertussis Filamentous Hemagglutinin (FHA). (Titers measured using an indirect, noncompetitive Pertussis enzyme immunoassay (EIA).)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Hepatitis B at 6 Weeks Postvaccination - GMT</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination Observed Geometric Mean Titer of Antibody to Hepatitis B. (Titers measured using the Quantitative AUSAB™ radioimmunoassay (RIA).)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Haemophilus Influenzae Type B (Hib) at 6 Weeks Postvaccination - GMT</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination observed GMT of antibody to Hib. (Anti-polyribosylribitol phosphate (PRP) was measured by RIA using radiolabeled-PRP according to a standard Farr technique and with a standard provided by the U.S. FDA.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Tetanus at 6 Weeks Postvaccination - GMT</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination Observed Geometric Mean Titer of Antibody to Tetanus. (Titers of tetanus antitoxin were measured with an indirect, noncompetitive enzyme immunoassay (EIA).)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1913</enrollment>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProQuad + Tripedia + Comvax at Day 0 (Concomitant)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProQuad at Day 0, Tripedia + Comvax at Day 42(Nonconcomitant)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Varivax + M-M-R II at Day 0, Tripedia + Comvax at Day 42 (Control)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live</intervention_name>
    <description>A single 0.5 mL subcutaneous injection at Day 0</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>ProQuad</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Tripedia</intervention_name>
    <description>A single 0.5 mL intramuscular injection (at Day 0 or Day 42)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Comvax</intervention_name>
    <description>A single 0.5 mL intramuscular injection (at Day 0 or Day 42)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Varivax</intervention_name>
    <description>A single 0.5 mL subcutaneous injection at Day 0</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: M-M-R II</intervention_name>
    <description>A single 0.5 mL subcutaneous injection at Day 0</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health

          -  Negative clinical history of varicella, zoster, measles, mumps, rubella, diptheria,
             tetanus, pertussis, invasive Hib disease and hepatitis B

          -  Had completed either a 2-dose primary series of PedvaxHIB or COMVAX or any 3-dose
             primary series of a licensed Hib vaccine

          -  Had received 2 or 3 doses of any hepatitis B vaccine or COMVAX prior to entry into
             trial

        Exclusion Criteria:

          -  Previous receipt of measles, mumps, rubella or varicella vaccine either alone or in
             combination

          -  Any immune impairment or deficiency

          -  Recent household, daycare or school exposure to invasive Hib disease or hepatitis B

          -  Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to
             vaccination

          -  Vaccination with an inactive vaccine with in the past 14 days

          -  Vaccination with a live vaccine within the past 30 days

          -  Receipt of immune globulin, blood transfusion or blood-derived product in the past 3
             months

          -  Recent history of fever or underlying medical problems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>15 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, Xu J, Hartzel J, Evans B, Digilio L, Schödel F, Brown ML, Kuter B; 013 Study Group for ProQuad. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatr Infect Dis J. 2006 Apr;25(4):287-92.</citation>
    <PMID>16567978</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <results_first_submitted>February 3, 2010</results_first_submitted>
  <results_first_submitted_qc>February 3, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2010</results_first_posted>
  <last_update_submitted>July 16, 2015</last_update_submitted>
  <last_update_submitted_qc>July 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rubella</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>48 clinical sites in the United States
Date first participant visit: 27-Jun-2000
Date last participant visit: 23-Oct-2001</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Concomitant Group</title>
          <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
        </group>
        <group group_id="P2">
          <title>Nonconcomitant Group</title>
          <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
        </group>
        <group group_id="P3">
          <title>Control Group</title>
          <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="949">2 patients were incorrectly vaccinated and are excluded from this table.</participants>
                <participants group_id="P2" count="485"/>
                <participants group_id="P3" count="479"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 1</title>
              <participants_list>
                <participants group_id="P1" count="949"/>
                <participants group_id="P2" count="485"/>
                <participants group_id="P3" count="479"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 2</title>
              <participants_list>
                <participants group_id="P1" count="909"/>
                <participants group_id="P2" count="468"/>
                <participants group_id="P3" count="453"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="884"/>
                <participants group_id="P2" count="453"/>
                <participants group_id="P3" count="442"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>CAE – discontinued test vaccine</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed one or more blood samplings</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incomplete safety follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Concomitant Group</title>
          <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
        </group>
        <group group_id="B2">
          <title>Nonconcomitant Group</title>
          <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
        </group>
        <group group_id="B3">
          <title>Control Group</title>
          <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="949"/>
            <count group_id="B2" value="485"/>
            <count group_id="B3" value="479"/>
            <count group_id="B4" value="1913"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.4" spread="0.7"/>
                    <measurement group_id="B2" value="12.3" spread="0.7"/>
                    <measurement group_id="B3" value="12.4" spread="0.7"/>
                    <measurement group_id="B4" value="12.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="442"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="246"/>
                    <measurement group_id="B4" value="911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="507"/>
                    <measurement group_id="B2" value="262"/>
                    <measurement group_id="B3" value="233"/>
                    <measurement group_id="B4" value="1002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="678"/>
                    <measurement group_id="B2" value="336"/>
                    <measurement group_id="B3" value="342"/>
                    <measurement group_id="B4" value="1356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥120 mIU/mL</title>
        <description>Antibody Response to Measles at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer &lt;120 mIU/mL) to Measles at Baseline</description>
        <time_frame>6 Weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥120 mIU/mL</title>
          <description>Antibody Response to Measles at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer &lt;120 mIU/mL) to Measles at Baseline</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="758"/>
                <count group_id="O2" value="388"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="741"/>
                    <measurement group_id="O2" value="383"/>
                    <measurement group_id="O3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥10 Ab Units/mL</title>
        <description>Antibody Response to Mumps at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer &lt;10 Ab units/mL) to Mumps at Baseline</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥10 Ab Units/mL</title>
          <description>Antibody Response to Mumps at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer &lt;10 Ab units/mL) to Mumps at Baseline</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="811"/>
                <count group_id="O2" value="415"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="774"/>
                    <measurement group_id="O2" value="395"/>
                    <measurement group_id="O3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥10 IU/mL</title>
        <description>Antibody Response to Rubella at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer &lt;10 IU/mL) to Rubella at Baseline</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥10 IU/mL</title>
          <description>Antibody Response to Rubella at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer &lt;10 IU/mL) to Rubella at Baseline</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="829"/>
                <count group_id="O2" value="421"/>
                <count group_id="O3" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="817"/>
                    <measurement group_id="O2" value="418"/>
                    <measurement group_id="O3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Varicella-Zoster Virus (VZV) Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Antibody Titer ≥5 gpELISA Units/mL</title>
        <description>Antibody Response to Varicella-Zoster Virus (VZV) at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer &lt;0.6 gpELISA units/mL) to VZV at Baseline</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants
who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to
varicella at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Varicella-Zoster Virus (VZV) Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Antibody Titer ≥5 gpELISA Units/mL</title>
          <description>Antibody Response to Varicella-Zoster Virus (VZV) at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer &lt;0.6 gpELISA units/mL) to VZV at Baseline</description>
          <population>The per-protocol analysis set included participants
who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to
varicella at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="757"/>
                <count group_id="O2" value="383"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="679"/>
                    <measurement group_id="O2" value="348"/>
                    <measurement group_id="O3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Diphtheria Vero Cell Culture Assay Antibody Titer ≥0.1 IU/mL</title>
        <description>Antibody response to Diphtheria at 6 weeks postvaccination</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Diphtheria Vero Cell Culture Assay Antibody Titer ≥0.1 IU/mL</title>
          <description>Antibody response to Diphtheria at 6 weeks postvaccination</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="675"/>
                <count group_id="O2" value="337"/>
                <count group_id="O3" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="667"/>
                    <measurement group_id="O2" value="333"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Tetanus Enzyme Immunoassay (EIA) Antibody Titer ≥0.1 IU/mL</title>
        <description>Antibody response to Tetanus (tetanus antitoxin were measured with an indirect, noncompetitive enzyme immunoassay (EIA)) at 6 weeks postvaccination.</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Tetanus Enzyme Immunoassay (EIA) Antibody Titer ≥0.1 IU/mL</title>
          <description>Antibody response to Tetanus (tetanus antitoxin were measured with an indirect, noncompetitive enzyme immunoassay (EIA)) at 6 weeks postvaccination.</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="803"/>
                <count group_id="O2" value="387"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="796"/>
                    <measurement group_id="O2" value="386"/>
                    <measurement group_id="O3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With ≥4-fold Rise in Pertussis Toxin (PT) EIA Antibody Titer</title>
        <description>Antibody response to Pertussis Toxin (titers of pertussis toxin antibodies were measured with an indirect, noncompetitive EIA).</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ≥4-fold Rise in Pertussis Toxin (PT) EIA Antibody Titer</title>
          <description>Antibody response to Pertussis Toxin (titers of pertussis toxin antibodies were measured with an indirect, noncompetitive EIA).</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="355"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="554"/>
                    <measurement group_id="O2" value="321"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With ≥4-fold Rise in Pertussis Filamentous Hemagglutinin (FHA) EIA Antibody Titer</title>
        <description>Antibody response to pertussis FHA(titers of pertussis filamentous hemagglutinin antibodies were measured with an indirect, noncompetitive EIA).</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ≥4-fold Rise in Pertussis Filamentous Hemagglutinin (FHA) EIA Antibody Titer</title>
          <description>Antibody response to pertussis FHA(titers of pertussis filamentous hemagglutinin antibodies were measured with an indirect, noncompetitive EIA).</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="502"/>
                    <measurement group_id="O2" value="309"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Hepatitis B (Quantitative AUSAB™ Radioimmunoassay (RIA)) Antibody Titer ≥10 mIU/mL</title>
        <description>Antibody response to Hepatitis B (titers measured using the Quantitative AUSAB™ radioimmunoassay (RIA)).</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Hepatitis B (Quantitative AUSAB™ Radioimmunoassay (RIA)) Antibody Titer ≥10 mIU/mL</title>
          <description>Antibody response to Hepatitis B (titers measured using the Quantitative AUSAB™ radioimmunoassay (RIA)).</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="825"/>
                <count group_id="O2" value="396"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="791"/>
                    <measurement group_id="O2" value="391"/>
                    <measurement group_id="O3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Haemophilus Influenzae Type B (Hib) Radioimmunoassay (RIA) Antibody Titer ≥ 1 mcg/mL</title>
        <description>Antibody response to Haemophilus influenzae type B (Hib). (Anti-polyribosylribitol phosphate (PRP) was measured by radioimmunoassay (RIA) using radiolabeled-PRP according to a standard Farr technique and with a standard provided by the U.S. FDA.)</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Haemophilus Influenzae Type B (Hib) Radioimmunoassay (RIA) Antibody Titer ≥ 1 mcg/mL</title>
          <description>Antibody response to Haemophilus influenzae type B (Hib). (Anti-polyribosylribitol phosphate (PRP) was measured by radioimmunoassay (RIA) using radiolabeled-PRP according to a standard Farr technique and with a standard provided by the U.S. FDA.)</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="822"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="778"/>
                    <measurement group_id="O2" value="384"/>
                    <measurement group_id="O3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Measles at 6 Weeks Postvaccination for Participants Initially Seronegative to Measles at Baseline - Geometric Mean Titer (GMT)</title>
        <description>Postvaccination Observed Geometric Mean Titer of Antibody to Measles. (Titers measured using Measles ELISA.)</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Measles at 6 Weeks Postvaccination for Participants Initially Seronegative to Measles at Baseline - Geometric Mean Titer (GMT)</title>
          <description>Postvaccination Observed Geometric Mean Titer of Antibody to Measles. (Titers measured using Measles ELISA.)</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="758"/>
                <count group_id="O2" value="388"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3504.9" lower_limit="3269.7" upper_limit="3757.2"/>
                    <measurement group_id="O2" value="3506.2" lower_limit="3195.7" upper_limit="3846.9"/>
                    <measurement group_id="O3" value="2562.1" lower_limit="2172.2" upper_limit="3022.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Mumps at 6 Weeks Postvaccination for Participants Initially Seronegative to Mumps at Baseline - GMT</title>
        <description>Postvaccination observed GMT of antibody to mumps. (Titers measured using mumps ELISA.)</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Mumps at 6 Weeks Postvaccination for Participants Initially Seronegative to Mumps at Baseline - GMT</title>
          <description>Postvaccination observed GMT of antibody to mumps. (Titers measured using mumps ELISA.)</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures.</population>
          <units>ELISA Ab units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="811"/>
                <count group_id="O2" value="415"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.4" lower_limit="83.5" upper_limit="95.7"/>
                    <measurement group_id="O2" value="84.1" lower_limit="76.2" upper_limit="92.8"/>
                    <measurement group_id="O3" value="98.1" lower_limit="85.7" upper_limit="112.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Rubella at 6 Weeks Postvaccination for Participants Initially Seronegative to Rubella at Baseline - GMT</title>
        <description>Postvaccination Observed Geometric Mean Titer of Antibody to Rubella. (Titers measured using Rubella ELISA.)</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Rubella at 6 Weeks Postvaccination for Participants Initially Seronegative to Rubella at Baseline - GMT</title>
          <description>Postvaccination Observed Geometric Mean Titer of Antibody to Rubella. (Titers measured using Rubella ELISA.)</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="829"/>
                <count group_id="O2" value="421"/>
                <count group_id="O3" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="92.8" upper_limit="105.0"/>
                    <measurement group_id="O2" value="99.9" lower_limit="91.8" upper_limit="108.7"/>
                    <measurement group_id="O3" value="126.3" lower_limit="111.9" upper_limit="142.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Varicella at 6 Weeks Postvaccination for Participants Initially Seronegative to Varicella at Baseline - GMT</title>
        <description>Postvaccination Observed Geometric Mean Titer of Antibody to Varicella. (Titers measured using VZV gpELISA.)</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Varicella at 6 Weeks Postvaccination for Participants Initially Seronegative to Varicella at Baseline - GMT</title>
          <description>Postvaccination Observed Geometric Mean Titer of Antibody to Varicella. (Titers measured using VZV gpELISA.)</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>gpELISA units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="757"/>
                <count group_id="O2" value="383"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="12.8" upper_limit="14.8"/>
                    <measurement group_id="O2" value="15.4" lower_limit="13.8" upper_limit="17.0"/>
                    <measurement group_id="O3" value="15.8" lower_limit="13.8" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Diphtheria at 6 Weeks Postvaccination - GMT</title>
        <description>Postvaccination Observed Geometric Mean Titer of Antibody to Diphtheria. (Titers measured using Vero Cell Culture Assay.)</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Diphtheria at 6 Weeks Postvaccination - GMT</title>
          <description>Postvaccination Observed Geometric Mean Titer of Antibody to Diphtheria. (Titers measured using Vero Cell Culture Assay.)</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="675"/>
                <count group_id="O2" value="337"/>
                <count group_id="O3" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="1.24" upper_limit="1.43"/>
                    <measurement group_id="O2" value="1.72" lower_limit="1.55" upper_limit="1.89"/>
                    <measurement group_id="O3" value="1.59" lower_limit="1.29" upper_limit="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Pertussis Toxin (PT) at 6 Weeks Postvaccination - GMT</title>
        <description>Postvaccination Observed Geometric Mean Titer of Antibody to Pertussis Toxin (PT). Titers measured using an indirect, noncompetitive Pertussis enzyme immunoassay (EIA).</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Pertussis Toxin (PT) at 6 Weeks Postvaccination - GMT</title>
          <description>Postvaccination Observed Geometric Mean Titer of Antibody to Pertussis Toxin (PT). Titers measured using an indirect, noncompetitive Pertussis enzyme immunoassay (EIA).</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="355"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="39.5" upper_limit="46.5"/>
                    <measurement group_id="O2" value="55.7" lower_limit="49.7" upper_limit="62.4"/>
                    <measurement group_id="O3" value="46.3" lower_limit="35.0" upper_limit="61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Pertussis Filamentous Hemagglutinin (FHA) at 6 Weeks Postvaccination - GMT</title>
        <description>Postvaccination Observed Geometric Mean Titer of Antibody to Pertussis Filamentous Hemagglutinin (FHA). (Titers measured using an indirect, noncompetitive Pertussis enzyme immunoassay (EIA).)</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Pertussis Filamentous Hemagglutinin (FHA) at 6 Weeks Postvaccination - GMT</title>
          <description>Postvaccination Observed Geometric Mean Titer of Antibody to Pertussis Filamentous Hemagglutinin (FHA). (Titers measured using an indirect, noncompetitive Pertussis enzyme immunoassay (EIA).)</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1" lower_limit="53.7" upper_limit="62.9"/>
                    <measurement group_id="O2" value="81.2" lower_limit="73.5" upper_limit="89.7"/>
                    <measurement group_id="O3" value="65.0" lower_limit="49.6" upper_limit="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Hepatitis B at 6 Weeks Postvaccination - GMT</title>
        <description>Postvaccination Observed Geometric Mean Titer of Antibody to Hepatitis B. (Titers measured using the Quantitative AUSAB™ radioimmunoassay (RIA).)</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Hepatitis B at 6 Weeks Postvaccination - GMT</title>
          <description>Postvaccination Observed Geometric Mean Titer of Antibody to Hepatitis B. (Titers measured using the Quantitative AUSAB™ radioimmunoassay (RIA).)</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="825"/>
                <count group_id="O2" value="396"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="758" lower_limit="658" upper_limit="874"/>
                    <measurement group_id="O2" value="996" lower_limit="828" upper_limit="1199"/>
                    <measurement group_id="O3" value="1135" lower_limit="836" upper_limit="1541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Haemophilus Influenzae Type B (Hib) at 6 Weeks Postvaccination - GMT</title>
        <description>Postvaccination observed GMT of antibody to Hib. (Anti-polyribosylribitol phosphate (PRP) was measured by RIA using radiolabeled-PRP according to a standard Farr technique and with a standard provided by the U.S. FDA.)</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Haemophilus Influenzae Type B (Hib) at 6 Weeks Postvaccination - GMT</title>
          <description>Postvaccination observed GMT of antibody to Hib. (Anti-polyribosylribitol phosphate (PRP) was measured by RIA using radiolabeled-PRP according to a standard Farr technique and with a standard provided by the U.S. FDA.)</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="822"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="10.1" upper_limit="12.3"/>
                    <measurement group_id="O2" value="12.1" lower_limit="10.6" upper_limit="13.7"/>
                    <measurement group_id="O3" value="12.9" lower_limit="10.4" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Tetanus at 6 Weeks Postvaccination – GMT</title>
        <description>Postvaccination Observed Geometric Mean Titer of Antibody to Tetanus. (Titers of tetanus antitoxin were measured with an indirect, noncompetitive enzyme immunoassay (EIA).)</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Group</title>
            <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Group</title>
            <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Tetanus at 6 Weeks Postvaccination – GMT</title>
          <description>Postvaccination Observed Geometric Mean Titer of Antibody to Tetanus. (Titers of tetanus antitoxin were measured with an indirect, noncompetitive enzyme immunoassay (EIA).)</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="803"/>
                <count group_id="O2" value="387"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" lower_limit="3.59" upper_limit="4.31"/>
                    <measurement group_id="O2" value="5.74" lower_limit="5.13" upper_limit="6.42"/>
                    <measurement group_id="O3" value="4.36" lower_limit="3.67" upper_limit="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed for safety for 42 days after Visit 1 and 14 days after Visit 2 (56 days total).</time_frame>
      <desc>Number of participants reported as &quot;At Risk&quot; is the number of participants with follow-up.
Although a subject may have had 2 or more adverse experiences, the subject is counted only once within a category. The same subject may appear in different categories.</desc>
      <group_list>
        <group group_id="E1">
          <title>Concomitant Group</title>
          <description>Concomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) + TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) + COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 0.</description>
        </group>
        <group group_id="E2">
          <title>Nonconcomitant Group</title>
          <description>Nonconcomitant Group - ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
        </group>
        <group group_id="E3">
          <title>Control Group</title>
          <description>Control Group - M-M-R™ II (measles, mumps, and rubella vaccine) and VARIVAX™ (varicella virus vaccine) administered concomitantly at separate injection sites on Day 0 and TRIPEDIA™ (diphtheria and tetanus toxoids and acellular pertussis vaccine) and COMVAX™ (haemophilus b conjugate and hepatitis B vaccine) administered concomitantly at separate injection sites on Day 42.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Merck CRISP</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy, food</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Cellulitis, orbital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia, inguinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Afebrile seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Seizure, febrile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Necrosis, testicle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Laryngotracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>Merck CRISP</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="831" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="435" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="411" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Pain, Ear</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="295" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="136" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Viral</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Gastroenteritis, Infectious</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Infection, Respiratory, Upper</sub_title>
                <counts group_id="E1" subjects_affected="258" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Viral Exanthema</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Bite/Sting, Non-Venomous</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Congestion, Nasal</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Congestion, Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Laryngotracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Dermatitis, Contact</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Miliaria Rubra</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Rash, Diaper</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Rash, Measles/Rubella-Like</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Rash, Varicella-Like</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Ecchymosis (ProQuad Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness/Soreness (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="308" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash (ProQuad Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness/Soreness (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="121" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Swelling (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Erythema (M-M-R II Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness/Soreness (M-M-R II Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="125" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Swelling (M-M-R II Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Ecchymosis (Tripedia Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Erythema (Tripedia Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="244" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness/Soreness (Tripedia Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="327" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Swelling (Tripedia Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Ecchymosis (Comvax Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Erythema (Comvax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="266" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Induration (Comvax Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness/Soreness (Comvax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="327" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="139" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Swelling (Comvax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="929"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Two participants were incorrectly vaccinated and are not included in the efficacy/safety analyses. One received M-M-R™II+TRIPEDIA™+COMVAX™ and 1 received VARIVAX™+TRIPEDIA™+COMVAX™ instead of ProQuad™+TRIPEDIA™+COMVAX™</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

